ライフサイエンスコーパス: anthrax vaccine

1 ax Vaccine Adsorbed (AVA, the licensed human anthrax vaccine).

2 ewanella CPS conjugates as a component of an anthrax vaccine.

3 mas from individuals immunized with licensed anthrax vaccine.

4 ipheral blood of subjects vaccinated with an anthrax vaccine.

5 n (rPA) of Bacillus anthracis is a promising anthrax vaccine.

6 ation and improves tolerability of a subunit anthrax vaccine.

7 pment of a Salmonella-based orally delivered anthrax vaccine.

8 ncies, with 385 following at least 1 dose of anthrax vaccine.

9 women, 3136 received at least 1 dose of the anthrax vaccine.

10 h the current and proposed "next-generation" anthrax vaccines.

11 for inducing protective immunity to PA-based anthrax vaccines.

12 ization that is important for currently used anthrax vaccines.

13 d, nonreactogenic, more-efficacious PA-based anthrax vaccines.

14 o expand the immunity conferred by available anthrax vaccines.

15 tant of a nonencapsulated, toxigenic strain (anthrax vaccine absorbed [AVA]) whose primary protective

16 a from human vaccinees immunized with rPA or anthrax vaccine absorbed and nonhuman primates immunized

17 Anthrax vaccine adsorbed (AVA) immunization raised antib

18 llus anthracis in subjects that received the anthrax vaccine adsorbed (AVA) vaccine were examined.

19 We identified spore targets of Anthrax Vaccine Adsorbed (AVA)-induced immunity in human

20 nduct a pivotal safety and efficacy study of anthrax vaccine adsorbed (AVA).

21 NAs were at least equivalent to two doses of anthrax vaccine adsorbed (AVA).

22 healthy subjects following immunization with Anthrax Vaccine Adsorbed (AVA).

23 nd boost the protective immunity elicited by Anthrax Vaccine Adsorbed (AVA, the licensed human anthra

24 otides containing unmethylated CpG motifs to Anthrax vaccine adsorbed (AVA, the licensed human vaccin

25 Exposed individuals received antibiotics and anthrax vaccine adsorbed immunization.

26 eys that received 14 days of antibiotic plus anthrax vaccine adsorbed survived (P = 0.011).

27 Guinea pigs vaccinated with Anthrax Vaccine Adsorbed were challenged with 20 B. anth

28 doses of the licensed human anthrax vaccine (anthrax vaccine adsorbed) after exposure.

29 existing vaccines (AVP and the U.S. vaccine anthrax vaccine adsorbed), macaques immunized with rPA r

30 ble to vaccination with the licensed vaccine anthrax vaccine adsorbed.

31 protective Ag of Bacillus anthracis in both anthrax vaccine-adsorbed vaccinees and nonvaccinees with

32 (rPA)--the major component of new-generation anthrax vaccines--affects vaccine immunogenicity, we cre

33 s reactogenic than currently available human anthrax vaccines, and could be self-administered without

34 o received three doses of the licensed human anthrax vaccine (anthrax vaccine adsorbed) after exposur

35 immunoprotective properties of plant-derived anthrax vaccine antigen.

36 We therefore took a nasal anthrax vaccine approach to attempt to induce protective

37 Existing licensed anthrax vaccines are administered parenterally and requi

38 These data demonstrate that KBMA anthrax vaccines are well tolerated and elicit potent pr

39 acilitate development of a cleaner and safer anthrax vaccine at a lower production cost.

40 s with protective antigen (PA), the chemical anthrax vaccine AVA, or Sterne spore vaccine, as well as

41 duals vaccinated with the currently approved anthrax vaccine BioThrax.

42 eceived a booster with either PA or licensed anthrax vaccine (BioThrax; Emergent Biosolutions) only o

43 toxin, is the major component in the current anthrax vaccine, but the fine antigenic structure of PA

44 his study paves the way for a more effective anthrax vaccine by identifying discontinuous peptide epi

45 adults immunized with AVA (immune sera), the anthrax vaccine currently approved for use by humans in

46 We developed a dually active anthrax vaccine (DAAV) that confers simultaneous protect

47 These findings are important for future anthrax vaccine development and treatment.

48 G) isolated from a subject immunized with an anthrax vaccine enhanced the killing of Sterne to 0.49 a

49 to be an important constituent of any future anthrax vaccine, evaluation of the efficacies of the var

50 ective efficacy of several live, recombinant anthrax vaccines given in a single-dose regimen was asse

51 In response to bioterrorism threats, anthrax vaccine has been used by the US military and con

52 In an effort to produce anthrax vaccine in large quantities and free of extraneo

53 future recognition of this disease; current anthrax vaccine information; updated antibiotic therapeu

54 The U.S.-licensed anthrax vaccine is made from an incompletely characteriz

55 making biological weapons, but the licensed anthrax vaccine is unsuitable for widespread public admi

56 ponent of anthrax toxin elicited by approved anthrax vaccines is an accepted correlate for vaccine-me

57 Improving next-generation anthrax vaccines is important to safeguard citizens and

58 suggests that protective antigen (PA)-based anthrax vaccines may elicit a narrow neutralizing antibo

59 urrounds the potential health effects of the anthrax vaccine, particularly the potential adverse effe

60 ulin G and TNA responses, suggesting that an anthrax vaccine patch is feasible and should advance int

61 Anthrax vaccine patches stimulated robust and functional

62 nsively for anthrax pathogenesis studies and anthrax vaccine potency testing, is a good candidate for

63 ng licensed vaccine from the United Kingdom (anthrax vaccine precipitated [AVP]), although the isotyp

64 72 h later whereas a single dose of licensed anthrax vaccine protected only 10%.

65 The currently available commercial human anthrax vaccine requires multiple injections for efficac

66 This potentially could lead to a needle-free anthrax vaccine requiring fewer doses and having fewer s

67 necessary and sufficient for adhesion of the anthrax vaccine strain, Bacillus anthracis Sterne, to ho

68 protective efficacy of the live, recombinant anthrax vaccine strains correlated with the anti-PA anti

69 In nonhuman primates, the success of this anthrax vaccine strategy based on heterologous mucosal p

70 report, we describe the improved potency of anthrax vaccines through the use of a dominant-negative

71 ed when making decisions about administering anthrax vaccine to pregnant women.

72 A new anthrax vaccine under clinical investigation is based on

73 have developed a novel whole-bacterial-cell anthrax vaccine utilizing B. anthracis that is killed bu

74 To evaluate the MAPs as potential anthrax vaccines, we immunized groups of rabbits (n = 7)

75 Four different anthrax vaccines were constructed by cloning the protect

76 The anthrax vaccines were produced by assembling the vectors

77 f rPA could represent the next generation of anthrax vaccines, which could require fewer doses becaus

78 sired characteristic of vaccines, especially anthrax vaccines, which must be stockpiled for large-sca

79 parenterally, such as the aluminum-adsorbed anthrax vaccine, will most likely not induce the needed